Hyperferritinemia Has Multifactorial Etiology in Naive Patients with Chronic Hepatitis C

Ibrahim Ahmad Hussein El Bacha*, Maria Cristina Elias, Ivonete Sandra de Souza e Silva, Ayk Helena Barbosa Martins and Edison Roberto Parise

Departamento de Medicina, Disciplina de Gastroenterologia, Universidade Federal de São Paulo Ibrahim, Brazil

Submission: June 15, 2020; Published: July 10, 2020

*Corresponding author: Ibrahim Ahmad Hussein El Bacha, Departamento de Medicina, Disciplina de Gastroenterologia, Universidade Federal de São PauloRua Loefgren, 1726– São Paulo – SP CRP 04040-002, Brazil

Abstract

Background & Aim: Traditionally, elevated serum ferritin is related to the presence of iron accumulation in the body, especially in the liver. However, in chronic hepatitis C several other factors have been alternatively associated with hyperferritinemia, such as liver enzymes, metabolic factors, hepatic steatosis and liver fibrosis. This study aimed to evaluate the exact contribution of these variables to ferritin serum levels in chronic hepatitis.

Methods: Naïve patients with chronic hepatitis C were selected retrospectively and their ferritin serum levels were correlated with demographic data (age and gender), biochemical (AST, ALT, GGT, ALP and glucose by automated methods; insulin by immunofluorimetry), virological (viral load and genotyping) and histological variables (degree of steatosis, inflammation and staging). Statistical analysis was performed by ANOVA complemented by Dunn's test and logistic regression analysis.

Results: In two hundred and eighty-two patients with mean age of 50 years and a predominance of male patients (56%) and genotype 1 (65%), the mean serum ferritin levels were 561 ng/mL for males and 270 ng/mL for females with a significant difference in ferritin levels between genders, irrespective of age. The mean HOMA-IR was 3.23 Histological examination showed that 23.4% of the patients had liver cirrhosis, 64.2% fatty liver, and 20% hepatic siderosis. The factors independently associated with hyperferritinemia in multivariate logistic regression analysis were ALT (p = 0.037), GGT (p < 0.001), hepatic siderosis (p = 0.002), steatosis (p = 0.027), and HOMA-IR (p = 0.014).

Conclusion: In treatment-naïve patients with chronic hepatitis C, hyperferritinemia has a multifactorial etiology.

Keywords: Serum ferritin; Siderosis; HOMA-IR; Steatosis; Hepatic fibrosis; Chronic hepatitis C

Abbreviations: HCV: hepatitis C Virus; HBV: Hepatitis B Virus; HIV: Human Immunodeficiency Virus; PCR: Polymerase Chain Reaction; AST: Alanine Aminotransferase; ALT: Aspartate Aminotransferase; GGT: Gamma- Glutamyl Transferase; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; PPA: Periportal Activity

Introduction

Hyperferritinemia is a frequent finding in chronic hepatitis C and affects about 20 to 30% of patients; however, only a small percentage of these patients show evidence of iron accumulation in tissue [1,2]. The increase in ferritin associated with iron overload in patients with chronic hepatitis C has been attributed to alterations in the secretion of hepcidin, a hormone secreted by the liver that regulates intestinal iron absorption [3,4] as well as to other concomitant diseases such as hereditary hemochromatosis, hematological diseases, multiple blood transfusions, porphyria cutanea tarda, chronic alcoholism, and hemodialysis. In the absence of siderosis, hyperferritinemia in hepatitis C has also been associated with inflammatory activity such as acute-phase proteins, tumor growth and, recently, abnormal glucose metabolism especially in the presence of type 2 diabetes mellitus [5-7]. In addition, increased levels of this transport protein are related to the presence of hepatic steatosis and oxidative stress, and the response to antiviral therapy with interferon [8,9].

Considering the large number of factors that have been associated with hyperferritinemia in patients with chronic hepatitis C, the objective of the present study was to evaluate the correlation of serum ferritin levels with demographic, histological and biochemical (liver enzymes and insulin resistance syndrome) parameters in treatment-naïve patients with chronic hepatitis C.
Materials and Methods

This was a retrospective study that evaluated the records of patients chronically infected with hepatitis C virus (HCV), followed up at the Liver Disease Outpatient Clinic of the Department of Gastroenterology, Unileps. Patients who met the following criteria were included: infection with HCV (confirmed by the detection of HCV-RNA in serum), liver biopsy with a diagnosis of chronic hepatitis, and determination of blood ferritin levels.

Exclusion criteria were coinfection with HBV and/or HIV, chronic alcohol consumption (> 20 g/day), presence of debilitating diseases, use of immunosuppressors, previous antiviral therapy, a history of multiple blood transfusions, iron replacement therapy, known hematological disease, known chronic systemic diseases, current or past gastrointestinal bleeding, hepatocellular carcinoma, and other known neoplasms.

HCV-RNA was investigated and quantified in serum by the polymerase chain reaction (PCR) using the Cobas Amplicor Test (Roche Diagnostic System, USA), with a detection limit of 50 IU/mL. Genotyping of HCV was performed by sequencing of the 5’UTR region. Serum levels of alanine aminotransferase (AST), aspartate aminotransferase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase, and glucose were measured by an automated kinetic method. Serum ferritin was determined by chemiluminescence, with the maximum normal limit of the central laboratory being 400 ng/mL for men and 150 ng/mL for women, regardless of age. These values were used as cut-offs for the categorization of ferritin. Altered blood glucose was defined as levels ≥ 100 mg/mL. Serum insulin was determined by an immunofluorimetric assay (Perkin Elmer BR-CS). The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated using the formula HOMA-IR = [glucose (nmol/L) * insulin (mU/mL) / 22.5] [10] and an index > 2.5 was considered to be altered [11].

Biopsy specimens were routinely submitted to hematoxylin-eosin staining, silver staining of reticulin fibers (Gomori method), and staining with Masson’s trichrome. The classification of necroinflammatory activity and staging of chronic hepatitis were performed using the criteria of the Brazilian Societies of Pathology and Hepatology [12]. The histological variables were categorized as the presence or absence of steatosis and liver siderosis (0 x 1, 2 and 3). Inflammatory activity was classified according to the perportal activity (PPA) as absent or mild versus moderate or intense (PPA 0 and 1 x PPA 2, 3 and 4) and structural alterations according to the presence or absence of advanced fibrosis (F0-F2 x F3,F4). For the semi-quantitative analysis of iron, the liver tissue fragments were stained with Prussian blue (Perls method). This analysis included the grading of liver siderosis using a system ranging from 0 to 4, where grade 0 (absence of iron deposits), grade 1 (iron granules visible at 400x magnification), grade 2 (discrete iron granules visible at 100x magnification), grade 3 (iron granules visible at 25x magnification), and grade 4 (mass of iron granules visible at 10x magnification or with the naked eye) [13]. Using this system, the patients were classified as having absent or mild liver siderosis (grades 0 and 1) or intense siderosis (grades 2 to 4).

Statistical analysis was performed using the SPSS 10 program. Mean values of the continuous variables were compared by analysis of variance (ANOVA), complemented by Dunn’s test. The c² test was used to compare frequencies and Spearman’s coefficient to evaluate the correlation between the variables studied. Binary logistic regression analysis was performed after categorization of the variables. The liver enzyme cut-offs were determined from receiver operating characteristic (ROC) curves.

Results

A total of 282 patients with chronic hepatitis C were included in the study. The demographic, biochemical, virological and histological data of the patients are shown in Tables 1 & 2. The patients with chronic hepatitis C were divided into four groups according to gender and age (Table 3). Significant differences in ferritin levels were observed between men and women, regardless of age. However, there was no significant difference in ferritin between patients < 50 and ≥ 50 years in the same gender.

Table 1: Demographic, biochemical and virological characteristics of the 282 patients with chronic hepatitis C.

| Parameter          | N = 282 |
|--------------------|---------|
| Gender (F/M)       | 124 (44%) / 158 (56%) |
| Age (years)        | 50.1 ± 12.8 |
| BMI (kg/m²)        | 25.4 ± 5.3 |
| AST (x ULN)        | 1.86 ± 1.85 |
| ALT (x ULN)        | 2.41 ± 2.44 |
| GGT (x ULN)        | 1.69 ± 1.76 |
| Alkaline phosphatase (x ULN) | 0.89 ± 0.59 |
| Platelets (count/mm³) | 185.3 ± 68.9 |
| Glucose (mg/dL)    | 98.8 ± 26.2 |
| Insulin (mU/L)     | 13.2 ± 10.3 |
| HOMA-IR            | 3.23 ± 2.78 |
| Ferritin (µg/L)    | 56.1 ± 598 |
| Male               | 270 ± 335 |
| Female             | 102 (39%) |
| Viral load (IU/mL) | 158 (61%) |
| Genotype 1         | 183 (65%) |
| Non-1              | 99 (35%) |

Numerical values are expressed as mean ± Standard Deviation. N: Number; M: Male; F: Female; BMI: Body Mass Index; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance, Adopting the formula: Fasting Insulin (mU/mL) x Fasting Glucose (nmol/L)/22.5; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; GGT: Gamma-Glutamyl Transferase; ULN: Upper Limit of Normal.
Table 2: Histological characteristics of the found in the 282 patients with chronic hepatitis C according to the criteria of the Brazilian Societies of Pathology and Hepatology12.

| Parameter | N = 282 |
|-----------|---------|
| Stage     |         |
| 0         | 35 (12.4%) |
| 1         | 60 (21.3%) |
| 2         | 65 (23.0%) |
| 3         | 56 (19.9%) |
| 4         | 66 (23.4%) |

| PPA       |         |
|-----------|---------|
| 0         | 24 (08.5%) |
| 1         | 54 (19.1%) |
| 2         | 95 (33.7%) |
| 3         | 98 (34.8%) |
| 4         | 11 (03.9%) |

| Siderosis |         |
|-----------|---------|
| 0         | 224 (79.4%) |
| 1         | 35 (12.4%) |
| 2         | 21 (7.44%) |
| 3         | 2 (0.71%) |
| 4         | 0 (0.0%) |

| Steatosis |         |
|-----------|---------|
| 0         | 101 (35.8%) |

Table 3: Ferritin levels in patients with chronic hepatitis C (n=282) according to gender and age (< 50 or ≥ 50 years).

| Group               | N  | Serum Ferritin(ug/L) (Mean ± standard error) |
|---------------------|----|---------------------------------------------|
| Female < 50 years   | 49 | 273 ± 55*                                   |
| Female ≥ 50 years   | 75 | 267 ± 34*                                   |
| Male < 50 years     | 83 | 535 ± 62                                    |
| Male ≥ 50 years     | 75 | 590 ± 73                                    |

ANOVA complemented by Dunn’s test. (*) p<0.05 for comparison of females and males independent of age.

The differences observed justify the use of different cut-off values for gender, but not for the age groups considered, permitting logistic regression analysis to determine the factors associated with serum ferritin levels. The results of univariate and multivariate binary logistic regression analysis are shown in Table 4. The following variables were significantly associated with ferritinemia in univariate analysis (Table 4): gender, platelet count, AST, ALT, GGT, HOMA-IR, body mass index, histological stage, periportal activity, steatosis, and liver siderosis. However, only ALT, GGT, HOMA-IR, steatosis and siderosis were independently associated with serum ferritin levels.

Table 4: Binary logistic regression analysis of factors associated with hyperferritinemia in the 282 patients with chronic hepatitis C studied.

| Variable                | Univariate OR | p     | Multivariate OR | 95%CI | p     |
|-------------------------|---------------|-------|-----------------|-------|-------|
| Age (< or ≥ 50 years)   | 0.329         | 0.566 |                 |       |       |
| Gender (M/F)            | 12.083        | 0.001 |                 |       |       |
| BMI (< or ≥ 25 kg/m²)   | 11.072        | 0.001 |                 |       |       |
| Platelets (< or ≥ 150,000/mm³) | 7.664 | 0.006 |                 |       |       |
| AST (1.35 x ULN)        | 17.299        | <0.001|                 |       |       |
| ALT (1.65 x ULN)        | 19.92         | <0.001| 2.213           | 1.048-4.673 | 0.037* |
| GGT (1.40 x ULN)        | 32.568        | <0.001| 2.987           | 1.630-5.472 | <0.001* |
| Alkaline phosphatase (1.00 x ULN) | 1.966 | 0.161 |                 |       |       |
| HOMA-IR (< or ≥ 2.5)    | 36.741        | <0.001| 2.176           | 1.173-4.038 | 0.014* |
| Stage (0,1,2,3,4)       | 11.176        | 0.001 |                 |       |       |
| PPA (0,1,2,3,4)         | 10.545        | 0.001 |                 |       |       |
| Steatosis (0 1,2,3)     | 14.153        | <0.001| 1.918           | 1.078-3.413 | 0.027* |
| Siderosis (0 1,2,3)     | 20.142        | <0.001| 3.749           | 1.654-8.499 | 0.002* |
| Viral load (> or < 8 x 106 IU/mL) | 1.579 | 0.209 |                 |       |       |
| Genotype (1 /non-1)     | 0.067         | 0.796 |                 |       |       |

BMI: Body Mass Index; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance, Adopting the Formula: Fasting Insulin (mU/mL) x Fasting Glucose (mmol/L)/22.5; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; GGT: Gamma-Glutamyl Transferase; ULN: Upper Limit of Normal; PPA: Periportal Activity; OR: Odds Ratio; 95%CI: 95% Confidence Interval. The AST, ALT and GGT cut-off values were obtained from the ROC curve.
The levels of ALT in these patients were associated with periportal activity upon liver histology in univariate (score 13.984; p=0.001) and multivariate analysis (1.364 (1.030-1.805); p=0.030), confirming the relationship of this enzyme with inflammatory activity in the disease. On the other hand, liver steatosis was associated with age > 50 years (OR 1.029, p=0.008), HCV non-genotype 1 (OR 1.901, p=0.035), and elevated ferritin levels (OR 2.092, p=0.0015) (Table 5).

### Table 5: Multivariate logistic regression analysis of factors associated with elevation of serum gamma-glutamyl transferase levels in the patients with chronic hepatitis C studied.

| Variable       | OR     | 95%CI   | p       |
|----------------|--------|---------|---------|
| Ferritin (male > 400 μg/L; female > 150 μg/L) | 2.639  | 1.489-4.678 | 0.001* |
| HOMA-IR (< or ≥ 2.5) | 3.119  | 1.703-5.713 | <0.001* |
| Stage (0.1 x 3.4) | 1.536  | 1.215-1.941 | <0.001* |
| PPA (0.1 x 2.3,4) | 0.886  | -       | -       |
| Steatosis (0 x 1,2,3) | 1.194  | -       | -       |

The following variables were included in univariate analysis: gender, age, body mass index, alkaline phosphatase, AST, ALT, Ferritin, HOMA-IR, stage, PPA and steatosis, but only variables achieving statistical significance were submitted to multivariate analysis: Body Mass Index; HOMA-IR; Homeostasis Model Assessment of insulin resistance, adopting the formula: fasting insulin (mU/mL) × fasting glucose (mmol/L)/22.5; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; GGT: Gamma-Glutamyl Transferase; PPA: Periportal Activity. The AST, ALT and GGT cut-off values were obtained from the ROC curve.

**Discussion**

Epidemiological studies have indicated renal failure, hematological diseases, liver diseases, abusive alcohol consumption, neoplasms, and inflammatory diseases as the most common causes of hyperferritinemia in clinical practice [14,15]. In chronic hepatitis C, the prevalence of hyperferritinemia is highly variable depending on the method and cut-off value used and the population selection criteria. Regarding the latter factor, comparison of ferritin values according to age and gender (Table 1) showed that in fact gender and not age was the determinant factor of serum ferritin concentration. In the present series, considering the cut-off values adopted, 48% of the patients had elevated ferritin levels. This percentage agrees with the study of Lange et al. [16] who also used gender-specific cut-offs but is much higher than that reported by other authors [17,18]. Part of this prevalence can be attributed to the larger number of patients with liver cirrhosis (23.5% of patients) in our sample.

Despite the bias of a retrospectively analysis, with limitations in the clinical and laboratory assessment of patients such as the lack of genetic study for hemochromatosis, the sample of 282 patients is robust and we selected criteria that permitted homogeneous evaluation of the factors involved in the elevation of serum ferritin levels in patients chronically infected with HCV. Regression analysis identified serum ALT and GGT levels, HOMA-IR, steatosis and liver siderosis as factors that were independently associated with hyperferritinemia.

Whereas almost half the patients had hyperferritinemia, iron deposition in the liver was detected histologically in only 20% of cases in sinusoidal cells and/or hepatocytes, as reported in other studies. Silva et al. [17], studying 96 patients with chronic hepatitis C including 27% with elevated ferritin levels, found stainable iron upon histology in only 15.6%. The authors observed a significant correlation between this finding and hepatic iron concentration. It should be noted that elevated serum iron in tissue was only observed in 5% of the cases of that study [17, in agreement with Thorburn et al. [19] who identified elevated hepatic iron concentrations in only 3% and 10% of patients with chronic hepatitis C, respectively. As tissue iron cannot be responsible for all observed cases of elevated serum ferritin levels, factors other than liver siderosis seem to be associated with hyperferritinemia in chronic hepatitis C [20]. Numerous other factors have been related to the increase in serum ferritin, including insulin resistance of type 2 diabetes mellitus [21-23], metabolic syndrome, hepatic steatosis [10,24,25], increased oxidative stress [3,26,27], liver fibrosis stage [28,29] and inflammatory activity [20,26].

In the present study, an association was observed between ALT and ferritin, as also reported by other authors [30-32]. This independent relationship was even found in the presence of periportal activity and disease stage, suggesting that ALT overlaps the histological finding. However, sub-analysis showed that necroinflammatory activity expressed as periportal activity was indeed the main factor associated with the increase in ALT levels. This association of ALT with ferritin supports the concept of this parameter of iron metabolism as an inflammatory acute-phase protein.

Another factor associated with serum ferritin levels was GGT activity. Given that multiple factors are associated with the activity of this enzyme in hepatitis C [28,33], among our patients insulin resistance and disease stage were found to be independently associated with the activity of this enzyme (data not shown). The relationship between serum GGT levels and the degree of liver fibrosis has been recognized by several authors [17,34]. Elevated GGT in patients with steatosis and insulin resistance can be attributed to the presence of oxidative stress since this enzyme participates in the metabolism of conjugates of glutathione, the main antioxidant agent in the liver. This would also explain its relationship with ferritinemia, another marker of oxidative stress [8,35,36].

It should also be remembered that patients with chronic hepatitis C are a high-risk population for developing diabetes [37,38]. Using data from the Third National Health and Nutrition Examination Survey (NHANES-III), Shaheen et al. [24] found hepatitis C to be associated with insulin resistance (measured by HOMA-IR) and elevated ferritin levels. Serum level of this iron transporter were a strong predictor of insulin resistance and...
future development of type 2 diabetes, in agreement with our findings showing that hyperferritinemia in hepatitis C was directly related to the HOMA-IR index in both univariate and multivariate analysis. Supporting this relationship, in another study using multivariate logistic regression analysis, insulinemia and ferritin were also independently associated with HCV [39]. Lecube et al [38], studying 634 non-diabetic patients with chronic hepatitis C, also found diabetes mellitus to be the main factor associated with ferritin elevation. Furthermore, the relationship between insulin resistance and ferritinemia has been described in other populations [6,7,40]. The installation of insulin resistance is the link between HCV infection and a higher risk of type 2 diabetes in patients without other risk factors. This insulin resistance would result from the direct action of the viral core protein and/or release of inflammatory cytokines and may regress after viral elimination [41-44].

The prevalence of steatosis of 65% found in this series is similar to that reported in studies conducted at the same service or in a population of the same urban center [11,17]. The factors associated with hepatic steatosis in this study were ferritinemia, insulin resistance and non-genotype 1, which are known to be related to this histological alteration. Several studies have found an association between elevated serum ferritin and the presence and degree of steatosis in patients with hepatitis C and with liver diseases of other etiologies [8,25,45-47], demonstrating a causal relationship independent of the presence of HCV. It is believed that ferritinemia is related to an increase in oxidative stress, which favors alterations in glucose metabolism and hepatic steatosis in this group of patients because of the interference with the secretion of apolipoprotein B by hepatocytes [48].

In this study, we were unable to establish a direct relationship between fibrosis and ferritin, as observed by other authors [16,49], probably because three other factors associated with the degree of liver fibrosis may have masked the importance of this structural alteration in the logistic regression analysis, i.e., insulin resistance, siderosis and serum GGT activity. It should be remembered that insulin resistance is associated with the progression of liver disease in chronic HCV infection [1,44].

**Conclusion**

In conclusion, hyperferritinemia has a multifactorial etiology in treatment-naive patients with chronic hepatitis C and is related to liver siderosis, insulin resistance and hepatic steatosis, in addition to serum GGT and ALT activity. In this respect, the hepatic enzymes probably indirectly reflect the inflammatory activity (represented by ALT levels) and, to a lesser extent, the changes in hepatic structure (represented by GGT levels). Oxidative stress may be the common factor linking these conditions.

**References**

1. Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, et al. (2003) Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 35(3): 172-178.
2. Furutani T, Hino K, Okuda M, Gondo T, Nishina S, et al. (2006) Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 130(7): 2087-2098.
3. Fujita N, Horike S, Sugimoto R, Tanaka H, Iwasa M, et al. (2007) Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med 43(2): 353-362.
4. Nichina S, Hino K, Korenaga M, Vecchio C, Pietrangelo A, et al. (2008) Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice reducing hepcidin transcription. Gastroenterology 124(1): 226-238.
5. Stechmesse L, Eder SK, Wagner A, Patsch W, Feldman A, et al. (2016) Metabolomic profiling identifies potential pathways involved in the interaction of iron homeostasis with glucose metabolism. Mol Metab 6(1): 38-44.
6. Aguivre LG, Urrunaga-Paez D, Mocad-Mapielli E, Guarnizo-Poma M, Lazaro-Alcantara H, et al. (2017) High serum ferritin levels are associated with insulin resistance but not with impaired glucose tolerance in a healthy population. Diabetes Metab Syndr (Suppl 2): S983-S988.
7. Lecube A, Herández C, Simó R (2009) Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. Diabetes Metab 25(5): 403-410.
8. Licata A, Nebbia ME, Cabibbo G, Iacono GL, Barbara F, et al. (2009) Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol 15(17): 2132-2138.
9. Laeder JM, Lopez-Alonso G, Devesa MJ, Cunca F (2009) Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C. Rev Esp Enferm Dig 101(1): 31-40.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DE, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7): 412-419.
11. Oliveira AC, Parise ER, Catarino RM, Lanzoni V, Leite Môr MMB, et al. (2009) Insulin resistance and not steatosis is associated with modifications in oxidative stress markers in chronic hepatitis C, non-3 genotype. Free Rad Res 43(12): 1187-1194.
12. Gayotto LCC, Comité SBP/SBH (2000) Visão histórica e consenso nacional sobre a classificação das hepatites crônicas. Projeto do Clube de Patologia Hepática da Sociedade Brasileira de Patologia aprovado pela Sociedade Brasileira de Hepatologia. GED Gastroenterol Endosc Dig 19: 137-140.
13. Searle J, Kerr FFR, Halliday JW, Powell LW (2002) Iron storage disease. In: mm Sweeney RN, Burt AD, Portmann BCP, Isac KG, Scheuer PJ, Anthony PP (Eds.), Pathology of the liver. Churchill Livingstone, New York, USA, pp. 219-241.
14. Kaltwasser JP, Lothar-Thomas (1998) Clinical Laboratory Diagnostics. Frankfurt, TH-Books, pp. 278-281.
15. Kirchbaum B (2001) Profiling hemodialysis patients with high ferritin levels. Clin Nephrol 56(2): 117-123.
Hyperferritinemia Has Multifactorial Etiology in Naive Patients with Chronic Hepatitis C.

Ibrahim A H E B, Maria C E, Ivonete S d S S, Ayk H B M, Edison R P

Advanced Research in Gastroenterology & Hepatology

Hepatitis C, metabolic syndrome, patients.

Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, et al. (2005) Elevated serum tumor necrosis factor contributes to insulin resistance in non-cirrhotic patients with chronic hepatitis C. Curr Med Res Opin 21(4): 527-534.

Maeno T, Okumura A, Ishikawa T, Kato K, Sakakibara F, et al. (2003) Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 26(10): 2486-2491.

Maeno T, Okumura A, Ishikawa T, Kato K, Sakakibara F, et al. (2003) Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 18(12): 1358-1363.

Iwasaki T, Nakajima A, Yoneda M, Yamada Y, Mukasa K, et al. (2005) Correlation of hepatic steatosis with body mass index, serum ferritin level and hepatic fibrosis in Japanese patients with chronic hepatitis C. Hepatol Res 37(4): 263-269.

Ibrahim A H E B, Maria C E, Ivonete S d S S, Ayk H B M, Edison R P (2012) Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon- alpha and rBVabirin therapy. Hepatology 55(4): 1038-1047.

Silva RM, Sumida Y, Nakamasa K, Fukushima K, Yoshida N, Sakai K (2007) Evidence of oxidative stress as a cofactor of liver disease in chronic hepatitis C. Gut 50(2): 243-248.

Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, et al. (2000) Successful interferon therapy reverses enhanced hepatic iron deposition and serum iron values in patients with chronic hepatitis C. J Gastroenterol Hepatol 15(10): 1041-1050.

Lin TJ, Liao LY, Lin SY, Lin CL, Chang TA (2006) Influence of iron on the association of – glutamyl transpeptidase to platelet ratio with liver enzymes level at patients with type 2 diabetes mellitus. Med Arch 69(4): 251-255.

Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349(9055): 825-832.

Lee DH, Steffes MW, Jacobs DR Jr (2008) Can persistent organic pollutants explain the association between serum gamma-glutamyl transferase and type 2 diabetes? Diabetologia 51(3): 402-407.

Venturini D, Simão AN, Barbosa DS, Lavado EL, Narciso VE, et al. (2010) Increased oxidative stress, decreased total antioxidant capacity, and iron overload in untreated patients with chronic hepatitis C. Dig Dis Sci 55(4): 1120-1127.

Elsammak M, Refai W, Elsawaf A, Abdel-Fattah I, Elb Elatti E, et al. (2005) Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr Med Res Opin 21(4): 527-534.

Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T (2002) Response to Oncil. Insulin sensitivity in patients with chronic hepatitis C virus infection [letter]. Diabetes Care 25(10): 2142-2148.

Elsammak M, Refai W, Elsawaf A, Abdel-Fattah I, Elb Elatti E, et al. (2005) Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr Med Res Opin 21(4): 527-534.

Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T (2002) Response to Oncil. Insulin sensitivity in patients with chronic hepatitis C virus infection [letter]. Diabetes Care 25(10): 1900-1901.

Malaguarnera M, Di Fazio I, Romeo MA, Restuccia S, Laurino A, et al. (1997) Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus infection. J Gastroenterol Hepatol 12(1): 932-940.

Garrido-Serrano A, Guerrero Igea FJ, Lejeunez JA, Palomo Gil S, Grillo Reina A (2001) Hepatitis C virus infection, increased serum ferritin and hyperinsulinemia. Rev Esp Enferm Dig 93(10): 639-648.

Jehn M, Clark J, Guillard E (2004) Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27(10): 2422-2428.

Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T (2002) Response to Oncil. Insulin sensitivity in patients with chronic hepatitis C virus infection [letter]. Diabetes Care 25(10): 1900-1901.

Parise ER, Oliveira AC (2007) Insulin resistance in chronic hepatitis C. Arq Gastroenterol. 44: 178-184.

How to cite this article: Ibrahim A H E B, Maria C E, Ivonete S d S S, Ayk H B M, Edison R P. Hyperferritinemia Has Multifactorial Etiology in Naive Patients with Chronic Hepatitis C. Adv Res Gastroentero Hepatol, 2020;15(2): 555914. DOI: 10.19080/ARGH.2020.15.555914
